Ide-cel Appears Active in Almost Three-Fourths of Heavily Pretreated Patients with Myeloma

The BCMA-targeting CAR T-cell therapy yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news